Senti Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Senti Biosciences (SNTI).

Price Target Range — 6 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$11Upside to Avg. PT+3421.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 15, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$11→$12
Mar 30, 2026	Chardan Capital	Geulah Livshits	PT Cut	Buy	$13→$11
Dec 9, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$12→$13
Nov 21, 2025	Leerink Partners	Jeffrey La Rosa	Initiate	Outperform	$6
Oct 14, 2025	HC Wainwright & Co.	Emily Bodnar	Initiate	Buy	$12
Aug 8, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Jun 12, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Jun 6, 2025	Laidlaw & Co.	Yale Jen	Initiate	Buy	$15
May 2, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Dec 4, 2024	Chardan Capital	Geulah Livshits	PT Raise	Buy	$10→$12
Dec 2, 2024	Chardan Capital	Geulah Livshits	Maintained	Buy	$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $11 to $12.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

Leerink Partners analyst Jeffrey La Rosa initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Outperform rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.

Benzinga Newsdesk

Senti Biosciences Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Senti Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

People Also Watch

People Also Watch

Senti Biosciences Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Senti Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROChardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

PROChardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

PROChardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

PROLeerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

PROHC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

PROChardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

People Also Watch

People Also Watch

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12

PRO
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target